JANSSEN BIOTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1979-01-01
- Employees
- 10K
- Market Cap
- -
Clinical Trials
13
Active:2
Completed:8
Trial Phases
2 Phases
Phase 2:1
Phase 3:4
Drug Approvals
15
FDA:12
NMPA:3
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (80.0%)Phase 2
1 (20.0%)An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis
Active, not recruiting
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 537
- Registration Number
- NCT02808780
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
Phase 3
Terminated
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01962974
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Relapsed or Refractory Mantle Cell Lymphoma
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Biotech, Inc.
- Registration Number
- NCT01833039
An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis
Completed
- Conditions
- Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2015-07-21
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT01555606
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 478
- Registration Number
- NCT01550744
- Prev
- 1
- 2
- 3
- Next
News
Icotrokinra Shows Promising Phase 3 Results for Plaque Psoriasis Treatment
Phase 3 trials show Icotrokinra significantly improved skin clearance in adults and adolescents with moderate to severe plaque psoriasis.
Johnson & Johnson Seeks Approval for Darzalex in High-Risk Smoldering Multiple Myeloma
Johnson & Johnson has submitted applications to the FDA and EMA for Darzalex Faspro to treat high-risk smoldering multiple myeloma.